NEW YORK (GenomeWeb News) – German firm Evotec said today that it will buy the zebrafish screening operations of UK company Summit for around £500,000 ($754,000).

The small molecule drug developer plans to use the new Summit operations in Abingdon, UK, and in Singapore, to prioritize promising compounds early in the drug discovery process.

Summit had agreements with a number of drug makers, including a three-year alliance with Johnson & Johnson, and collaborations with Bayer-Schering, Merck KGaA, Roche, and others.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.